BioAtla (BCAB) Common Equity (2020 - 2026)
BioAtla (BCAB) posted quarterly Common Equity of -$37.3 million for Q1 2026, down 6920.66% year-over-year from $547000.0 in Q1 2025, and down 3.09% quarter-over-quarter from -$36.2 million in Q4 2025.
BioAtla (BCAB) Common Equity (2020 - 2026) Analysis & Trends
BioAtla's Common Equity history runs 7 years deep, the most recent figure standing at -$37.3 million for Q1 2026.
- In Q1 2026, Common Equity fell 6920.66% year-over-year to -$37.3 million; the TTM figure through Mar 2026 stood at -$37.3 million (down 6920.66% YoY), while the FY2025 annual figure was -$36.2 million, down 353.69% from the prior year.
- Common Equity for Q1 2026 stood at -$37.3 million, down from -$36.2 million in the prior quarter.
- The five-year high for Common Equity was $190.1 million in Q1 2022, with the low at -$37.3 million in Q1 2026.
- The 5-year median for Common Equity is $49.7 million (2024), against an average of $66.0 million.
- The sharpest annual moves came in 2022 and 2026: Common Equity slipped 2.99% in 2022, then plunged 6920.66% in 2026.
- BioAtla's Common Equity stood at $180.3 million in 2022, then sank by 60.81% to $70.7 million in 2023, then tumbled by 79.82% to $14.3 million in 2024, then plunged by 353.69% to -$36.2 million in 2025, then declined by 3.09% to -$37.3 million in 2026.
- Business Quant data shows BCAB's Common Equity at -$37.3 million in Q1 2026, -$36.2 million in Q4 2025, and -$31.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.57 Bn | 131.72 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.44 Bn | 60.25 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.06 Bn | 54.93 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.89 Bn | 28.58 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.11 Bn | 9.72 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 9.79 Bn |
| 10 | BioAtla | 5.57 Mn | 5.57 Mn | - | -36.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -36.24 Mn |
| Mar 31, 2026 | -37.31 Mn |
| Dec 31, 2025 | -36.19 Mn |
| Sep 30, 2025 | -31.24 Mn |
| Jun 30, 2025 | -16.75 Mn |
| Mar 31, 2025 | 547,000.00 |
| Dec 31, 2024 | 14.27 Mn |
| Sep 30, 2024 | 22.97 Mn |
| Jun 30, 2024 | 31.37 Mn |
| Mar 31, 2024 | 49.72 Mn |
| Dec 31, 2023 | 70.67 Mn |
| Sep 30, 2023 | 94.70 Mn |
| Jun 30, 2023 | 124.52 Mn |
| Mar 31, 2023 | 156.43 Mn |
| Dec 31, 2022 | 180.34 Mn |
| Sep 30, 2022 | 142.63 Mn |
| Jun 30, 2022 | 164.95 Mn |
| Mar 31, 2022 | 190.05 Mn |
| Dec 31, 2021 | 210.82 Mn |
| Sep 30, 2021 | 230.65 Mn |